Intervention

Orlistat 120 mg

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCTNCT07326839 · 2025-12-10

NOT_YET_RECRUITING

Orlistat Overcoming Third-generation EGFR-TKI ResistanceNCT06818955 · 2025-02-16

NOT_YET_RECRUITING

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese SubjectsNCT01126970 · 2010-04-01

Common conditions

Obesity2 Gout1 Lung Adenocarcinoma1 Osimertinib1

Leading sponsors

Ping Peng1 Shionogi1 XueMei Guo1

Trial status mix

NOT_YET_RECRUITING2

COMPLETED1

Phase mix

PHASE22

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.